Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBT (2016 - 2025)

Historic EBT for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $141.1 million.

  • Ligand Pharmaceuticals' EBT rose 232648.68% to $141.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.0 million, marking a year-over-year increase of 708.15%. This contributed to the annual value of $2.5 million for FY2024, which is 9604.46% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' EBT stood at $141.1 million, which was up 232648.68% from $11.2 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year EBT high stood at $141.1 million for Q3 2025, and its period low was -$65.4 million during Q2 2024.
  • Moreover, its 5-year median value for EBT was $11.2 million (2025), whereas its average is $14.6 million.
  • Per our database at Business Quant, Ligand Pharmaceuticals' EBT plummeted by 216212.55% in 2024 and then skyrocketed by 232648.68% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBT (Quarter) stood at $17.9 million in 2021, then skyrocketed by 35.0% to $24.1 million in 2022, then decreased by 29.18% to $17.1 million in 2023, then crashed by 329.28% to -$39.2 million in 2024, then skyrocketed by 460.04% to $141.1 million in 2025.
  • Its EBT stands at $141.1 million for Q3 2025, versus $11.2 million for Q2 2025 and -$50.2 million for Q1 2025.